World Class Drug Delivery Company
World Class Drug Delivery Company
BDD has world leading expertise in the development and clinical testing of innovative pharmaceutical products. Our development strategies are underpinned by our understanding of biopharmaceutics which has evolved over years of experience in visualising in vivo performance of products using gamma scintigraphy. This enables us to identify and anticipate drug delivery challenges and apply this knowledge to our formulation development projects from an early stage.
OralogiK™ is an oral drug delivery platform providing timed release, sustained release and the opportunity for complex release of one or multiple drugs. OralogiK™ gives you the opportunity to design a tablet with specific drug release profiles for improved therapeutic performance. This can be used to enhance patient lives and compliance as well as providing your product with a competitive edge.
For more than 20 years, BDD has worked with the smallest to the largest companies across the pharmaceutical, biotech and medical devices sectors providing a customised service that is appropriate for the phase and purpose of each clinical trial.
Gamma scintigraphy is a versatile, non-invasive, imaging technique offering you early-stage evaluation of drug delivery systems in vivo, in real-time. Ensure your drug is delivering reliably prior to downstream investment of scale-up and clinical phases.
By utilizing an adaptive clinical design, we evaluate and optimize your product performance using in vivo clinical data to direct formulation design in real time. This integrates formulation development, GMP manufacture and clinical testing in parallel to streamline your drug development and set you on a reliable path to commercial success.
“With industry leading scientific expertise in clinical imaging and drug product design, BDD was an ideal partner for early stage clinical evaluation of complex drug products and implementation of new imaging approaches.” – Matt Burke – Vice President, Technical Operations & Product Development.
Formerly Senior Director, Head of Drug Delivery and CMC Leader at GSK
“We are happy to collaborate with BDD Pharma – their technology as well as integrated setup for early exploratory clinical testing is a great match for us and allow us to advance our Parkinson´s disease program towards patients.” – Anders Brandt Elvang – Chief Business Officer
“BDD was able to think out of the box in approaching some unusual formulation challenges in our development program. We were able to work interactively with BDD to get our new drug formulation program off the ground.” – Thomas Jozefiak – Chief Scientific Officer
“Cingulate appreciates BDD’s collaborative approach which consistently takes into consideration our priorities. This has allowed us to progress our clinical program for our ADHD clinical candidate. We certainly can recommend BDD for anyone seeking a reliable partner.” – Laurie Myers – Chief Operating Officer
“We cannot thank this team enough for all the hard work that led us to this point! The flexibility, the promptness, the communication. One of the best sites we’ve worked with, a truly cohesive team.” – Kiana Robinson – Project Manager
World Class Drug Delivery Company
Glasgow Royal Infirmary
84 Castle St
Glasgow
G4 0SF, UK
+44 (0)141 552 8791
Bio-City Scotland
Bo’ness Road
Chapelhall, Newhouse
ML1 5UH, UK
+44 (0)141 404 9540
Contera Pharma and BDD Pharma announce dosing of first subject in a Phase 1 trial of CP-012, a novel formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease